Thalomid thalidomide: Phase II

Interim results from a Phase II trial showed that 77 percent of of 42 newly diagnosed patients who received Thalomid in combination with dexamethasone had a response (defined as ?50 percent reduction in serum and/or urine monoclonal protein), while 38 percent of patients receiving thalidomide alone responded. Skin toxicity seen with the 400 mg dose of Thalomid led to a reduction of the dose used of 200 mg.Thalomid is marketed by CELG to treat cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) in leprosy. Data were presented at the American Society of Hematology meeting in San Francisco. ...